Rutin trihydrate attenuated cisplatin- induced cardiac toxicity in isolated perfused rat’s hearts

Rutin trihydrate attenuated cisplatin- induced cardiac toxicity in isolated perfused rat’s hearts | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Rutin trihydrate attenuated cisplatin- induced cardiac toxicity in isolated perfused rat’s hearts Ishfaq Bukhari, Osama Yousif Mohamed, Rahmathunnisa Lateef, Sabiha Fatima, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-26078/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background The present study aims to investigate the protective effect of rutin against cisplatin induced toxic effects on the mechanical performance of the myocardium, histopathology, and oxidative stress in isolated perfused rat hearts. Methods Cardiotoxicity of cisplatin was assessed at three dosage levels (1, 7, and 14 mg/l) in the isolated perfused rat hearts. The toxic effect of cisplarin was assessed on left ventricular pressure (LVP), heart rate (HR), dp/dt(max), dp/dt (min), perfusion pressure, pressure-time index, contractility index and duration of diastole. Measurements were carried out one minute before perfusion of cisplatin and 60 minutes after perfusion. Results Cisplatin reduced significantly (p < 0.05) in a dose-dependent manner LVP, dp/dt(max), dp/dt(min) and pressure- time index. Perfusion of rutin trihydrate (1 µM/l), 10 minutes before administration of cisplatin and throughout the experiment significantly (p < 0.05) attenuated the detrimental effects of cisplatin on cardiac parameters. Cisplatin caused degeneration and necrosis of cardiac muscle cells, while rutin reduced these changes and restored normal heart histology. Moreover, cisplatin reduced the myocardium concentration of reduced glutathione and increased the level of malondialdehyde, whereas rutin almost reversed these changes. Conclusion Cisplatin-induced dose-dependent impairment of several parameters of cardiac function and produced histopathological alterations in isolated rat hearts. These harmful effects of cisplatin were ameliorated by rutin trihydrate. These findings suggest the potential protective effects of rutin trihydrate against cisplatin-induced cardiotoxicity. General Practice cisplatin rutin trihydrate cardiac function histology oxidative stress Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Background Cisplatin is a broad spectrum anti malignant drug. It is widely used in in the management of testicular, ovarian, non-small cell lung cancer, gastric and esophageal cancers, and hematological malignancies [1]. The clinical use of cisplatin is significantly limited by its adverse effects and toxicities affecting the gastrointestinal, renal, neurological, and hematological systems [2]. Growing number evidences have revealed that cisplatin produced multiple cardio toxic effects such as unstable angina pectoris [3], cardiac arrhythmias [4], bradycardia [5], acute myocardial infarction [6], hypotension [7], atrioventricular block [8], cardiac failure [9] and cardiomyopathy [10]. Increase in oxidative stress and decrease in antioxidant enzymes are linked with cardio-toxic effects of cisplatin [11]. Rutin has been reported for beneficial protective effects against variety of drug induced toxicities including doxorubicin and cisplatin induced cardiac toxicity and memory deficits [12–14]. These protective effects of rutin are related to its profound antioxidant and anticancer properties. Considering this hypothesis, the efficacy of rutin against cisplatin-induced cardiac toxicity was investigated. It is also an established fact that therapeutic effect of cisplatin is significantly increased with the increased dose [15], but at the cost of severe adverse effects [16]. Keeping this in mind the dose dependent cardiotoxicity of cisplatin was explored. The data related to prophylactic effect of rutin against dose dependent cisplatin-induced cardiotoxicity is scarce. Therefore, the focus of our study was to evaluate the protective effect of rutin on cisplatin induced derangements on mechanical performance of the myocardium, histopathology, and oxidative stress in isolated perfused rat hearts. Materials And Methods Mechanical performance of the heart Male rats of the Albino Wistar strain (250-350 g body weight, King Saud University breed), five groups (8 rats each) were used. The experiments were conducted following the ethical guidelines for investigation in laboratory animals, and the College of Medicine, KSU; Institutional Review Board (IRB) approved the protocol of the study. The rats were anesthetized with urethane and the hearts were removed and perfused with Krebs-Henseleit solution (composition in mM: NaCl 118.4, KCl 4.7, MgSO 4 1.2, K 2 HPO 4 1.2, NaHCO 3 25.0, CaCl 2 2.5, glucose 11.5) gassed with 95% O 2 ,5% CO 2 at a constant flow rate of 10 ml/ min and maintained at 37 0 C with LE Thermostat (Panlab, HARVARD APPARATUS, USA). A saline-filled latex balloon connected via a polyethylene tube to a pressure transducer (MLA844, ADInstruments,Spain) was inserted into the left ventricle, and a baseline enddiastolic pressure was set at 5–10mmHg. The pressure transducer was connected to ADInstrument Powerlab 8/30 via a bridge amplifier (ADInstruments, Sydney Australia). The perfusion pressure was monitored by a second pressure transducer (MLA844, ADInstruments,Spain) connected to ADInstrument Powerlab 8/30 via a bridge amplifier (ADInstruments, Sydney Australia). All hearts were allowed to perfuse for 15 minutes to achieve stabilization. Following the stabilization period, the parameters recorded are Left ventricular pressure (LVP), heart rate (HR), dp/dt (max), dp/dt (min), perfusion pressure, pressure-time index, contractility index and duration of diastole. Results were analyzed using Labchart pro 7 software. Measurements were carried out at one minute before perfusion of cisplatin (Ebewe Pharma, Austria) and 60 minutes after perfusion. In a separate group, rutin trihydrate (Sigma- Aldrich GmbH, Germany) was perfused for 10 minutes before administration of cisplatin and throughout the experiment. A third sham group was perfused with Krebs-Henseleit solution for 60 minutes. Responses obtained 60 minutes after perfusion were expressed as percentages in relation to those obtained at one minute before perfusion of cisplatin. Histopathological examination At the end of the experiment, specimens of the ventricles of control, cisplatin 14mg/l and rutin and cisplatin groups were dissected, divided into two portions, one for detecting the underlying structural changes and the other for endogenous antioxidants analysis. The first specimens were then fixed in 10% buffered formalin and processed with paraffin wax. For histopathological feature examination, 5 µm sections were stained with hematoxylin and eosin for the analysis using a light microscope. Analysis of endogenous antioxidants The other heart specimens were washed by PBS then further divided and stored at -80 o C till used for quantification of (GSH and MDA) the antioxidant / pro-oxidant variables. On the day of quantification, each specimen was weighed, homogenized in relevant specified buffers, centrifuged, and processed following the methodology of sample preparation for each estimate. Reduced Glutathione (GSH) Assay The principle is based on the reaction of reduced GSH with 5.5-dithiobis-(2-nitrobenzoic acid) (DTNB) (E. Merck Ltd., Bombay, India), according to the method of Owens and Belcher [17]. The absorbance was measured by Schimadzu double beam spectrophotometer (UV200S, Japan) at 412 nm. The amount of GSH present was calculated using a standard solution of GSH containing 1 mg of GSH/ml of 3% meta-phosphoric acid. The increase in the extinction at 412 nm was proportional to the amount of GSH present and was expressed as nmol/g wet tissue. Malondialdehyde (MDA) Assay The principle is based on the reaction of MDA with thiobarbituric acid (TBA) (E. Merck Ltd., Bombay, India), according to the method described by Buege and Aust [18]. The concentration of the MDA-TBA complex was being quantified spectrophotometrically at 532 nm and expressed as nmol/g wet tissue. Statistical analysis Data reported as mean ± SEM. One-way analysis of variance followed by Tukey’s multiple comparison tests as a post hoc test was used to analyze the data. A p-value of 0.05 or less was taken as a criterion for statistically significant differences. Data were analyzed using Graph Pad Prism 5 software. Results 1-Effect of cisplatin (1, 7, and 14 mg/l) on parameters of mechanical performance of the heart Table 1 depicts the effects of different concentrations of cisplatin (1, 7 and 14 mg/l) on left ventricular pressure, dp/dtmax, dp/dtmin, heart rate, contractility index and pressure- time index. Eight isolated hearts were perfused with Krebs solution containing different concentrations of cisplatin for 60 minutes. The response obtained at minute 60 is calculated as a percentage of the response obtained at the first minute before perfusion of hearts with cisplatin. All concentrations of cisplatin-induced a statistically significant (p < 0.01) and dose-dependent reduction in left ventricular pressure. Cisplatin at 7 and 14 mg/l concentrations, significantly (p < 0.05) reduced dp/dt max and dp/dt min. Cisplatin exerted a bell-shaped concentration-response relationship on heart rates. Cisplatin at 1 mg/l increased the heart rate significantly (P < 0.01), while 7 mg/l slightly reduced the heart rate. All three doses of cisplatin increased significantly (p < 0.01) the contractility index, whereas, Cisplatin 7 and 14 mg/l significantly (p < 0.05) reduced pressure- time index. Table 1 Effects of cisplatin (1, 7, and 14 mg/l) on parameters of mechanical performance of the isolated rat heart. Time/parameters LVP % +dp/dt % -dp/dt % HR % Contractility index % Pressure- time index % One min before 100 100 100 100 100 100 Untreated 60 min after 94 ± 9 101 ± 7 92 ± 8 101 ± 7 105 ± 3 92 ± 12 Cisplatin 1 mg/l,60 min after 70 ± 6** 97 ± 12 78 ± 7 145 ± 11** 138 ± 5** 74 ± 8 Cisplatin 7 mg/l, 60 min after 69 ± 5** 77 ± 3* 72 ± 5* 85 ± 6 140 ± 6** 68 ± 7* Cisplatin 14 mg/l, 60 min after 65 ± 4** 72 ± 5* 69 ± 4* 104 ± 7 151 ± 7** 57 ± 7* Cisplatin was perfused for 60 minutes. Measurement of parameters of mechanical performance was carried out one minute before and 60 minutes after administration of cisplatin. Parameters were expressed as percentages of values after 60 minutes versus those at one minute before administration of cisplatin. Sham experiment was intended to show the mechanical performance of the heart in absence of drugs after 60 minutes. Eight isolated rats were used in each group. *p < 0.05; **p < 0.001 2-Effects of rutin trihydrate (1 µM) on parameters of mechanical performance altered by cisplatin Table 2 shows the effects of rutin trihydrate (1 µM) on alterations of the mechanical performance of isolated rat hearts induced by cisplatin (14 mg/l). Rutin trihydrate (1 µM) was perfused 10 minutes before administration of cisplatin. Rutin (1 µM) significantly (p < 0.05) reversed the reduction of left ventricular pressure induced by perfusion of hearts with 14 mg/l cisplatin for 60 minutes and attenuated the reduction in dp/dt max and dp/dt min exerted by cisplatin. There was a trend for the heart rate to increase, when hearts were perfused for 60 minutes with cisplatin (14 mg/l), but this increase did not attain statistical significance. Perfusion of hearts with rutin (1 µM) significantly (p < 0.05) reduced heart rate. After 60 minutes of perfusion, cisplatin (14 mg/l) significantly (p < 0.05) increased contractility index. Perfusion of hearts with rutin (1 µM) significantly (p < 0.01) reversed this increase in contractility index and significantly (p < 0.01) reversed the reduction in pressure- time index induced by cisplatin. When hearts were perfused for 60 minutes with cisplatin(14 mg/l), there was a tendency for the duration of diastole to decrease, but perfusion of hearts with rutin (1 µM) significantly (p < 0.05) increased period of diastole. There was a trend for the perfusion pressure to increase, when hearts were perfused for 60 minutes with cisplatin (14 mg/l), but this increase was statistically non-significant. Perfusion of hearts with rutin (1 µM) significantly (p < 0.01) reduced perfusion pressure. Table 2 Effects of rutin trihydrate (1 µM) on parameters of mechanical performance altered by cisplatin (14 mg/l) in isolated hearts. Time/parameters LVP % +dp/dt % -dp/dt % HR % Contracti lity index Pressur e- time index Diastolic duration Perfusion pressure One min before 100 100 100 100 100 100 100 100 Untreated 60 min after 94 ± 9 101 ± 7 92 ± 8 101 ± 7 105 ± 3 92 ± 12 116 ± 7 166 ± 16 Cisplatin 14 mg/l, 60 min after 65 ± 4** 72 ± 5 * 69 ± 4 * 104 ± 7 151 ± 7** 57 ± 7 * 99 ± 12 117 ± 7 Cisplatin 14 mg/l + Rutin 1 µM,60 min after 84 ± 3 ## 85 ± 6 # 83 ± 4 # 86 ± 6 # 101 ± 7 ## 82 ± 5 ## 139 ± 17 # 84 ± 2 # Rutin trihydrate was administered 10 minutes before admiration of cisplatin(14 mg/l) to 8 isolated hearts. Parameters were expressed as percentages of values after 60 minutes versus those at one minute before administration of cisplatin. *p < 0.05 significantly different from untreated **p < 0.01 significantly different from untreated #p < 0.05 significantly different from cisplatin 14 mg/l, 60 minutes after. ##p < 0.01 significantly different from cisplatin 14 mg/l, 60 minutes after. Histological Examination Figure 1 : A specimen of the control group showed single, oval, and centrally located nuclei of cardiomyocytes with regularly arranged cardiac myofibers and no histopathological lesion observed in the control group. While cisplatin group showed degenerated muscle cells, necrosis of cardiac myofibers and dissolution of nuclei. The cardiac myofibres in this group were found to be in a disarrayed pattern compared to the control muscle (Fig. 2 ). Another specimen of cisplatin specimen showed degenerated muscle cells with interstitial edema (Fig. 3 ). Addition of rutin to hearts perfused with cisplatin 14 mg/l showed a reduction in the toxic changes and the normal heart histology was significantly restored (Fig. 4 ). Antioxidants Analysis Perfusion of hearts with cisplatin 14 mg/l significantly (p < 0.01) reduced the concentration of glutathione, while perfusion of hearts with both rutin and cisplatin approximately restored the concentration of the reduced form of glutathione (Fig. 5 ). Whereas, perfusion of hearts with cisplatin greatly and significantly (p < 0.01) increased the concentration of malondialdehyde. Addition of Rutin to the perfusate containing cisplatin greatly reduced the tissue concentration of malondialdehyde (Fig. 6 ). Discussion Cardiac dysfunction can be demonstrated by hemodynamic changes in various parameters of cardiac function. Parameters of cardiac function assessed in this study included left ventricular pressure, heart rate, dp/dt (max), dp/dt (min), perfusion pressure, pressure-time index, contractility index and duration of diastole. Data from this study revealed that cisplatin reduced significantly left ventricular pressure, dp/dt(max), dp/dt (min) and pressure -time index in the isolated rat heart in a dose-dependent manner after perfusion for 60 minutes. In the present study, histopathological findings of heart tissues depicted that cisplatin administration induced degeneration and necrosis of cardiac muscle with the dissolution of nuclei. These observations correlate well with the alterations of hemodynamic and mechanical function induced by cisplatin. Moreover, cisplatin increased lipid peroxidation in heart tissue and reduced antioxidant activity. Numerous injurious effects of cisplatin on the heart have been reported. Cisplatin has been shown to produce creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH) leakage, a progressive reduction in total carnitine and ATP and depletion of glutathione content in cardiac tissue [10]. It is also reported to produce a dose-dependent decrease in contractile force, heart rate, and coronary flow [19] and induce oxidative and nitrosative stress [10, 20]. Furthermore, it caused apoptosis [21], deterioration of diastolic cardiac function [22] oxidative stress, inflammation, and histopathological alterations [10]. Several mechanisms have been reported to explain the harmful effects of cisplatin on the myocardium. Cisplatin can generate reactive oxygen species, such as superoxide anion and hydroxyl radical [23]. These reactive oxygen species are associated with an increase in lipid peroxidation [24]. Lipid peroxidation of the cardiac membrane results in leakage of lactate dehydrogenase and creatinine kinase from cardiac myocytes [19]. Moreover, cisplatin induced a fall in plasma concentrations of various antioxidants [25]. This may lead to failure of the anti- oxidative defense mechanism against free radical-mediated organ damage. These effects are evident in the current study. Cisplatin increased lipid peroxidation, which is indicated by increased tissue concentration of malondialdehyde and reduced tissue antioxidant activity, which is indicated by reduced tissue reduced glutathione concentration. Glutathione has a direct antioxidant function by reacting with free radicals. This activity is useful in the detoxification of peroxidized lipids. Thus, it is likely that cisplatin-induced detrimental effect on the hemodynamic and mechanical function and histology of the myocardium, by increasing lipid peroxidation and reduction of glutathione tissue concentration. To overcome cisplatin-induced cardiotoxicity, numerous efforts have been made in the past [26]. In the present study, rutin trihydrate reversed the harmful effects of cisplatin on left ventricular pressure, dp/dt(max), dp/dt(min), contractility index, pressure- time index, heart rate, duration of diastole and perfusion pressure. Moreover, cisplatin restored the normal histology of the myocardium, inhibited lipid peroxidation, and increased reduced glutathione concentration. Coronary blood flow is impeded during systole, the duration of diastole is an important determinant of coronary blood flow and subendocardial perfusion. Rutin trihydrate by prolonging the duration of diastole and reducing perfusion pressure could greatly improve coronary blood flow and subendocardial perfusion. Cisplatin causes cardio-toxic effects by oxidative stress and decrease in antioxidant enzymes [11]. Rutin has been previously reported for beneficial protective effects against variety of drug induced toxicities including doxorubicin and cisplatin induced cardiac toxicity [12–14]. The protective effects of rutin trihydrate observed in our current study mostly likely occurred due to its profound anti-oxidant properties. This protective effect of rutin trihydrate could be attributed to its antioxidant property. Rutin trihydrate has been shown to enhance superoxide dismutase (SOD) and 1,1-diphenyl-2-picrylhydrazyl (DPPH) activity [27] and reduced lipid peroxide content increased by cisplatin in kidneys of rats [28–29]. Moreover, rutin is reported to have anti-inflammatory and anti-apoptotic effects. It inhibited NFκB and TNF-α pathway mediated inflammation and caspase-3 cell apoptosis [30]. Conclusion Cisplatin-induced dose-dependent impairment of several parameters of cardiac function, induced histopathological alterations, and reduced antioxidant activity. These harmful effects of cisplatin were ameliorated by rutin trihydrate. Cisplatin the ability of rutin to ameliorate cisplatin-induced cardiotoxicity could be attributed to its antioxidant effects. The attenuation of the detrimental effects of cisplatin by rutin trihydrate could have eventual clinical implications in terms of more rational usage of this agent. Rutin trihydrate appears to be a potential candidate to ameliorate cardiotoxicity associated with cisplatin in rats. Hence, it would be worthwhile studying the effects of rutin trihydrate supplementation in cisplatin-treated cancer patients, in the hope of reducing cisplatin-induced cardiotoxicity. Abbreviations CK-MB: creatine kinase-MB; DTNB: 5.5-dithiobis-(2 nitrobenzoic acid; +dp/dt(max):Rate of maximum change of left ventricular contraction; -dp/dt(min): rate of minimum change of left ventricular relaxation; GSH: Reduced glutathione; LDH: lactate dehydrogenase; LVP: left ventricular pressure; MDA: Malondialdehyde; TNF-α: Tumor necrosis factor alpha; TBA: thiobarbituric acid Declarations Acknowledgement The authors extend their appreciation to the Deanship of Scientific Research at King Saud University, Riyadh for funding this work through research group (RG–1439–002). Authors’ contributions IAB is the main author, contributed in funding, methodology, analyzed the data, wrote and revised the manuscript. OY contributed in the methodology and helped and data analysis and revising the manuscript. RL contributed in the experimental work and data compilation and manuscript writing. SF contributed in the experimental work and data compilation. FV contributed in the literature review and data anlysis. SA contribute in data compilation, analysis and literature review and data. Funding There is no funding to declare. Availability of data and materials The authors confirm that the data supporting the findings of this study are available within the article. Ethics approval and consent to participate The experiments were conducted following the ethical guidelines for investigation in laboratory animals, and the College of Medicine, King Saud University Riyadh. Consent for publication Not applicable Competing Interests The authors declare that they have no competing interests. References Sleijfer DTh, Meijer S,Mulder NH. Cisplatin: a review of clinical applications and renal Pharm Weekbl [Sci]. 1985;7: 237-44. Tsang RY , Al - Fayea T , Au HJ. Cisplatin overdose: toxicities and management. Drug Saf . 2009; 32:1109-22. Khan S, Chen CL, Brady MS, Parameswaran R , Moore R , Hassoun H , Carvajal RD . Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma. J Clin Oncol. 2012; 30: e163–4. Tassinari D, Sartori S, Drudi G, Panzini I, Gianni L, Pasquini E, Abbasciano V , Ravaioli A , Iorio D. Clinical case; Cardiac arrhythmias after cisplatin infusion: Three case reports and a review of the literature. Ann of Oncol. 1997; 8:1263-1267. Kucharz J, Michalowska-Kaczmarczyk A, Zygulska AL, Wojtak J, Pawlik W,Herman RM, Krzemieniecki K. Bradycardia as a rare symptom of cisplatin cardiotoxicity. Oncol Lett. 2016;11:2297-2299. Sawant SP, Prakruthi J, Daddi AD, Ghosh J , Joshi A , Dhir Cisplatin-induced cardiotoxicity – two case reports. Onco Rev . 2015 ; 5 : A145-150. Jakubowski AA, Kemeny N. Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. Cancer 1988 ; 62: 266–269. Ozcan T , Cirit A, Kiykim A. Recurrent Complete atrioventricular block during cisplatin infusion.A case report. J Clinic Experiment Cardiol. 2011; 2:151. Brillet G, Deray G, Baumelou A, Jacobs C. Acute cardiac and renal failure after 5FU and cisplatin treatment. Nephron 1991; 59:667-668. Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa MA, Al-Rejaie SS, AlShabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin- induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006; 53: 278– 286. Demir F, Narin F, Akgün H, Üzüm K, Saraymen R, Baykan A, et al. Effects of melatonin on experimental cardiotoxicity induced by doxorubicin. Çocuk Sağ Hast Derg. 2004; 47: 260-8. Fei J, Sun Y, Duan Y, Xia J, Yu S, Ouyang P, Wang T, Zhang G. Low concentration of rutin treatment might alleviate the cardiotoxicity effect of pirarubicin on cardiomyocytes via activation of PI3K/AKT/mTOR signaling pathway. Biosci Rep. 2019; 39(6). Topal İ, Özbek Bilgin A, Keskin Çimen F, Kurt N, Süleyman Z, Bilgin Y, Özçiçek A, Altuner D. The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol J Cardiol. 2018;136-142. Ramalingayya GV, Cheruku SP, Nayak PG, Kishore A, Shenoy R, Rao CM, Krishnadas N. Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats. Drug Des Devel Ther. 2017;10: 11-1026. Sabuncuoğlu S, Özgüneş H. Cisplatin toxicity: Importance of oxidative stress and effect of antioxidants. J Ist Faculty Med. 2011; 74: 18-25. Sakamoto M, Kaga K, Kamio T. Extended high-frequency ototoxicity induced by the first administration of cisplatin. Otolaryngol Head Neck Surg. 2000; 122: 828-33. Owens CW, Belcher RV. A colorimetric micro-method for the determination of glutathione biochem j. 1965; 94:705-11. Buege JA, Aust SD. Microsomal lipid peroxidation. Method Enzymol. 1978; 52:302-10. Misic MM , Jakovljevic VL , Bugarcic ZD , Zivkovic VI , Srejovic IM , Barudzic NS , Djuric DM , Novokmet SS . Platinum Complexes-Induced cardiotoxicity of isolated perfused rat heart: Comparison of Pt (II) and Pt (IV) Analogues Versus Cisplatin. Cardiovasc. Toxicol. 2015;15: 261-8. Demkow U, Białas-Chromiec B, Stelmaszczyk-Emmel A, Radzikowska E, Wiatr, E, Radwan-Rohrenschef P, Szturmowicz M. The cardiac markers and oxidative stress parameters in advanced non-small cell lung cancer patients receiving cisplatin-based chemotherapy. eJIFCC. 2011; 14:6-15. El-Sawalhi MM, Ahmed LA. Exploring the protective role of apocynin, a specific NADPH oxidase inhibitor in cisplatin-induced cardiotoxicity in rats. Chem Biol Interact . 2014; 207:58-66. Altena R , de Haas EC , Nuver J , Brouwer CA , van den Berg MP , Smit AJ , Postma A , Sleijfer DT , Gietema JA. Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br. J. Can. 2014; 100:1861-1866. Wozniak K , Czechowska A , Blasiak J . Cisplatin- evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Chemo Biol Inter. 2004; 147:309-318. Antunes LM , Darin JD , Bianchi MD . Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res. 2011; 41:405-411. Weijl NI , Hopman GD , Wipkink - Bakker A . Lentjes EG , Berger HM , Cleton FJ Osanto S . Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol .1998; 2000: 1331-7. 20 - El - Awady SE , Moustafa YM , Abo - Elmatty DM , Radwan A . Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol . 2011; 650: 335-41. 21 - Bhandary B , Piao CS , Kim DS , Lee GH , Chae SW , Kim HR , Chae HJ. The Protective Effect of Rutin against ischemia/reperfusion-associated hemodynamic alteration through antioxidant activity. Arch Pharm Res. 2012; 35: 1091-1097. Kamel KM , Abd El - Raouf OM , Metwally SA , Abd El - Latif HA , El - sayed ME . Hesperidin and rutin, antioxidant citrus flavonoids, attenuate cisplatin-induced nephrotoxicity in rats. J Biochem Mol Toxicol . 2014; 28: 312-9. Sreedevi A, Bharathi K , Prasad Protective Effect of Rutin against cisplatin-induced nephrotoxicity in rats. J Nat Rem. 2010 ; 10: 144 - 151 . Arjumand W , Seth A , Sultana S . Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NFκB, TNF-α and caspase-3 expression in wistar rats. Food Chem Toxicol . 2011; 49: 2013-21. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-26078","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research","associatedPublications":[],"authors":[{"id":549328,"identity":"7ca06236-673c-4b41-9a0b-fb055b447489","order_by":1,"name":"Ishfaq Bukhari","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA1ElEQVRIiWNgGAWjYBACAwY2NiAlAUTMBxgYG0jTwpZAkhaQLh4D4rSYS6SlPfi5xyLfXLrnm8TPHTZyDOyHj27Ap8VyRtpxw55nEpY755zdJtl7Js2YgSct7QZeh91Ib5PgOSBhYHAjd5sEb9vhxAYJHjOCWiT/gLXkPJP8S5yWtGPSEFty2KSJssWy51matAxQC9BTxtaybWnGbIT8Ys6eZib55kCdgblE8sObb9ts5PjZDx/DqwXhQgYGFgkQg40o5VAtzB+IVj0KRsEoGAUjCgAAtkdIjL0TE28AAAAASUVORK5CYII=","orcid":"","institution":"King Saud University College of Medicine","correspondingAuthor":true,"prefix":"","firstName":"Ishfaq","middleName":"","lastName":"Bukhari","suffix":""},{"id":549329,"identity":"f02c5d80-2417-4944-8c13-fac697a839a9","order_by":2,"name":"Osama Yousif Mohamed","email":"","orcid":"","institution":"King Saud University College of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Osama","middleName":"Yousif","lastName":"Mohamed","suffix":""},{"id":549330,"identity":"53488f0b-35ae-426a-9319-0d158d016aca","order_by":3,"name":"Rahmathunnisa Lateef","email":"","orcid":"","institution":"King Saud University College of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Rahmathunnisa","middleName":"","lastName":"Lateef","suffix":""},{"id":549331,"identity":"2af46836-19d9-4f57-ab7b-ff8f66ef092c","order_by":4,"name":"Sabiha Fatima","email":"","orcid":"","institution":"King Saud University College of Applied Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Sabiha","middleName":"","lastName":"Fatima","suffix":""},{"id":549332,"identity":"3dd07eb4-22cf-4e18-a40e-a6c2d65edd31","order_by":5,"name":"Fahim Vohra","email":"","orcid":"","institution":"King Saud University College of Dentistry","correspondingAuthor":false,"prefix":"","firstName":"Fahim","middleName":"","lastName":"Vohra","suffix":""},{"id":549333,"identity":"7ea2ecd7-3aba-4eee-b502-aab4a24a3b3a","order_by":6,"name":"Sibtain Afzal","email":"","orcid":"","institution":"King Saud University College of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Sibtain","middleName":"","lastName":"Afzal","suffix":""}],"badges":[],"createdAt":"2020-04-29 06:14:27","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-26078/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-26078/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":1072199,"identity":"a0ef838f-38ac-4180-9747-1c8b050ce741","added_by":"auto","created_at":"2020-05-11 19:11:55","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":87178,"visible":true,"origin":"","legend":"Control group showed single, oval and centrally located nuclei of cardiomyocytes with regularly arranged cardiac myofibers. No histopathological lesion observed in control group.","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-26078/v1/1.jpg"},{"id":1072200,"identity":"1e8bec16-534d-4517-83b2-5c07a78512e9","added_by":"auto","created_at":"2020-05-11 19:11:55","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":52130,"visible":true,"origin":"","legend":"Cisplatin Group depicts degenerated muscle cells, necrosis of cardiac myofibers, and dissolution of nuclei in cardiac myofibers. The cardiac myofibers in this group were found to be in disarrayed pattern compared to the control muscle.","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-26078/v1/2.jpg"},{"id":1072201,"identity":"8349d878-fd7f-4350-8c22-3abbaee7768a","added_by":"auto","created_at":"2020-05-11 19:11:55","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":544224,"visible":true,"origin":"","legend":"Cisplatin Group showing degenerated muscle cells and interstitial edema (arrows) (cisplatin 14mg/l).","description":"","filename":"3.PNG","url":"https://assets-eu.researchsquare.com/files/rs-26078/v1/3.PNG"},{"id":1072202,"identity":"99d458a7-bfca-4b10-952f-ee0db44f545e","added_by":"auto","created_at":"2020-05-11 19:11:55","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":75746,"visible":true,"origin":"","legend":"Rutin+cisplatin group shows reduction in the toxic changes and the normal heart histology is significantly restored. (Cisplatin 14mg/l, rutin 1µM).","description":"","filename":"4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-26078/v1/4.jpg"},{"id":1072203,"identity":"24953e62-e2df-4a33-bca0-ca1f62bc493a","added_by":"auto","created_at":"2020-05-11 19:11:56","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":74698,"visible":true,"origin":"","legend":"Effect of rutin (1µM) on reduction of reduced glutathione concentration induced by 14mg cisplatin following perfusion for 60 minutes. Tissues from 8 isolated hearts were used to quantify reduced glutathione. p\u003c0.01 significantly different from control, # p\u003c0.01 significantly different from cisplatin 14mg/l.","description":"","filename":"5.PNG","url":"https://assets-eu.researchsquare.com/files/rs-26078/v1/5.PNG"},{"id":1072204,"identity":"9b22b8a7-af80-4dee-9f82-f99d0b2aefdf","added_by":"auto","created_at":"2020-05-11 19:11:56","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":57028,"visible":true,"origin":"","legend":"Effect of rutin (1µM) on increase of MDA concentration induced by 14mg cisplatin following perfusion for 60 minutes. Tissues from 8 isolated hearts were used to quantify malondialdehyde. p\u003c0.01 significantly different from control, # p\u003c0.01 significantly different from cisplatin 14mg/l.","description":"","filename":"6.PNG","url":"https://assets-eu.researchsquare.com/files/rs-26078/v1/6.PNG"},{"id":13502819,"identity":"292b9109-bfc9-4fbb-bdc5-455875208db8","added_by":"auto","created_at":"2021-09-16 23:16:19","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1141188,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-26078/v1/b4f22ab1-e991-4d90-aab0-c605ce339149.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003eRutin trihydrate attenuated cisplatin- induced cardiac toxicity in isolated perfused rat’s hearts\u003c/p\u003e","fulltext":[{"header":"Background","content":" \u003cp\u003eCisplatin is a broad spectrum anti malignant drug. It is widely used in in the management of testicular, ovarian, non-small cell lung cancer, gastric and esophageal cancers, and hematological malignancies [1]. The clinical use of cisplatin is significantly limited by its adverse effects and toxicities affecting the gastrointestinal, renal, neurological, and hematological systems [2].\u003c/p\u003e \u003cp\u003eGrowing number evidences have revealed that cisplatin produced multiple cardio toxic effects such as unstable angina pectoris [3], cardiac arrhythmias [4], bradycardia [5], acute myocardial infarction [6], hypotension [7], atrioventricular block [8], cardiac failure [9] and cardiomyopathy [10].\u003c/p\u003e \u003cp\u003eIncrease in oxidative stress and decrease in antioxidant enzymes are linked with cardio-toxic effects of cisplatin [11]. Rutin has been reported for beneficial protective effects against variety of drug induced toxicities including doxorubicin and cisplatin induced cardiac toxicity and memory deficits [12\u0026ndash;14]. These protective effects of rutin are related to its profound antioxidant and anticancer properties. Considering this hypothesis, the efficacy of rutin against cisplatin-induced cardiac toxicity was investigated. It is also an established fact that therapeutic effect of cisplatin is significantly increased with the increased dose [15], but at the cost of severe adverse effects [16]. Keeping this in mind the dose dependent cardiotoxicity of cisplatin was explored. The data related to prophylactic effect of rutin against dose dependent cisplatin-induced cardiotoxicity is scarce. Therefore, the focus of our study was to evaluate the protective effect of rutin on cisplatin induced derangements on mechanical performance of the myocardium, histopathology, and oxidative stress in isolated perfused rat hearts.\u003c/p\u003e "},{"header":"Materials And Methods","content":"\u003cp\u003eMechanical performance of the heart\u003c/p\u003e\n\u003cp\u003eMale rats of the Albino Wistar strain (250-350 g body weight, King Saud University breed), five groups (8 rats each) were used. The experiments were conducted following the ethical guidelines for investigation in laboratory animals, and the College of Medicine, KSU; Institutional Review Board (IRB) approved the protocol of the study. The rats were anesthetized with urethane and the hearts were removed and perfused with Krebs-Henseleit solution (composition in mM: NaCl 118.4, KCl 4.7, MgSO\u003csub\u003e4\u003c/sub\u003e 1.2, K\u003csub\u003e2\u003c/sub\u003eHPO\u003csub\u003e4\u003c/sub\u003e 1.2, NaHCO\u003csub\u003e3 \u003c/sub\u003e25.0, CaCl\u003csub\u003e2\u003c/sub\u003e 2.5, glucose 11.5) gassed with 95% O\u003csub\u003e2\u003c/sub\u003e ,5% CO\u003csub\u003e2\u003c/sub\u003e at a constant flow rate of 10 ml/ min and maintained at 37\u003csup\u003e0\u003c/sup\u003eC with LE Thermostat (Panlab, HARVARD APPARATUS, USA). A saline-filled latex balloon connected via a polyethylene tube to a pressure transducer (MLA844, ADInstruments,Spain) was inserted into the left ventricle, and a baseline enddiastolic pressure was set at 5\u0026ndash;10mmHg. The pressure transducer was connected to ADInstrument Powerlab 8/30\u003c/p\u003e\n\u003cp\u003evia a bridge amplifier (ADInstruments, Sydney Australia). The perfusion pressure was monitored by a second pressure transducer (MLA844, ADInstruments,Spain) connected to ADInstrument Powerlab 8/30 via a bridge amplifier (ADInstruments, Sydney Australia). All hearts were allowed to perfuse for 15 minutes to achieve stabilization. Following the stabilization period, the parameters recorded are Left ventricular pressure (LVP), heart rate (HR), dp/dt (max), dp/dt (min), perfusion pressure, pressure-time index, contractility index and duration of diastole. Results were analyzed using Labchart pro 7 software. Measurements were carried out at one minute before perfusion of cisplatin (Ebewe Pharma, Austria) and 60 minutes after perfusion. In a separate group, rutin trihydrate (Sigma- Aldrich GmbH, Germany) was perfused for 10 minutes before administration of cisplatin and throughout the experiment. A third sham group was perfused with Krebs-Henseleit solution for 60 minutes. Responses obtained 60 minutes after perfusion were expressed as percentages in relation to those obtained at one minute before perfusion of cisplatin.\u003c/p\u003e\n\u003cp\u003eHistopathological examination\u003c/p\u003e\n\u003cp\u003eAt the end of the experiment, specimens of the ventricles of control, cisplatin 14mg/l and rutin and cisplatin groups were dissected, divided into two portions, one for detecting the underlying structural changes and the other for endogenous antioxidants analysis. The first specimens were then fixed in 10% buffered formalin and processed with paraffin wax. For histopathological feature examination, 5 \u0026micro;m sections were stained with hematoxylin and eosin for the analysis using a light microscope.\u003c/p\u003e\n\u003cp\u003eAnalysis of endogenous antioxidants\u003c/p\u003e\n\u003cp\u003eThe other heart specimens were washed by PBS then further divided and stored at -80\u003csup\u003eo\u003c/sup\u003eC till used for quantification of (GSH and MDA) the antioxidant / pro-oxidant variables. On the day of quantification, each specimen was weighed, homogenized in relevant specified buffers, centrifuged, and processed following the methodology of sample preparation for each estimate.\u003c/p\u003e\n\u003cp\u003eReduced Glutathione (GSH) Assay\u003c/p\u003e\n\u003cp\u003eThe principle is based on the reaction of reduced GSH with 5.5-dithiobis-(2-nitrobenzoic acid) (DTNB) (E. Merck Ltd., Bombay, India), according to the method of Owens and Belcher [17]. The absorbance was measured by Schimadzu double beam spectrophotometer (UV200S, Japan) at 412 nm. The amount of GSH present was calculated using a standard solution of GSH containing 1 mg of GSH/ml of 3% meta-phosphoric acid. The increase in the extinction at 412 nm was proportional to the amount of GSH present and was expressed as nmol/g wet tissue. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMalondialdehyde (MDA) Assay\u003c/p\u003e\n\u003cp\u003eThe principle is based on the reaction of MDA with thiobarbituric acid (TBA) (E. Merck Ltd., Bombay, India), according to the method described by Buege and Aust [18]. The concentration of the MDA-TBA complex was being quantified spectrophotometrically at 532 nm and expressed as nmol/g wet tissue.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eStatistical analysis\u003c/p\u003e\n\u003cp\u003eData reported as mean \u0026plusmn; SEM. One-way analysis of variance followed by Tukey\u0026rsquo;s multiple comparison tests as a post hoc test was used to analyze the data. A p-value of 0.05 or less was taken as a criterion for statistically significant differences. Data were analyzed using Graph Pad Prism 5 software.\u003c/p\u003e"},{"header":"Results","content":" \u003cp\u003e1-Effect of cisplatin (1, 7, and 14\u0026nbsp;mg/l) on parameters of mechanical performance of the heart Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e depicts the effects of different concentrations of cisplatin (1, 7 and 14\u0026nbsp;mg/l) on left ventricular pressure, dp/dtmax, dp/dtmin, heart rate, contractility index and pressure- time index. Eight isolated hearts were perfused with Krebs solution containing different concentrations of cisplatin for 60 minutes. The response obtained at minute 60 is calculated as a percentage of the response obtained at the first minute before perfusion of hearts with cisplatin. All concentrations of cisplatin-induced a statistically significant (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) and dose-dependent reduction in left ventricular pressure. Cisplatin at 7 and 14\u0026nbsp;mg/l concentrations, significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) reduced dp/dt max and dp/dt min. Cisplatin exerted a bell-shaped concentration-response relationship on heart rates. Cisplatin at 1\u0026nbsp;mg/l increased the heart rate significantly (P\u0026thinsp;\u0026lt;\u0026thinsp;0.01), while 7\u0026nbsp;mg/l slightly reduced the heart rate. All three doses of cisplatin increased significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) the contractility index, whereas, Cisplatin 7 and 14\u0026nbsp;mg/l significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) reduced pressure- time index.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eEffects of cisplatin (1, 7, and 14\u0026nbsp;mg/l) on parameters of mechanical performance of the isolated rat heart.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTime/parameters\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLVP %\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e+dp/dt\u003c/p\u003e \u003cp\u003e%\u003c/p\u003e\u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-dp/dt\u003c/p\u003e \u003cp\u003e%\u003c/p\u003e\u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eHR %\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eContractility index %\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003ePressure- time index %\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOne min before\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUntreated 60\u0026nbsp;min after\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e94\u0026thinsp;\u0026plusmn;\u0026thinsp;9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e101\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e92\u0026thinsp;\u0026plusmn;\u0026thinsp;8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e101\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e105\u0026thinsp;\u0026plusmn;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e92\u0026thinsp;\u0026plusmn;\u0026thinsp;12\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCisplatin\u003c/p\u003e \u003cp\u003e1\u0026nbsp;mg/l,60\u0026nbsp;min\u003c/p\u003e \u003cp\u003eafter\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e70\u0026thinsp;\u0026plusmn;\u0026thinsp;6**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e97\u0026thinsp;\u0026plusmn;\u0026thinsp;12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e78\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e145\u0026thinsp;\u0026plusmn;\u0026thinsp;11**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e138\u0026thinsp;\u0026plusmn;\u0026thinsp;5**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e74\u0026thinsp;\u0026plusmn;\u0026thinsp;8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCisplatin 7\u0026nbsp;mg/l, 60\u0026nbsp;min after\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e69\u0026thinsp;\u0026plusmn;\u0026thinsp;5**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e77\u0026thinsp;\u0026plusmn;\u0026thinsp;3*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e72\u0026thinsp;\u0026plusmn;\u0026thinsp;5*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e85\u0026thinsp;\u0026plusmn;\u0026thinsp;6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e140\u0026thinsp;\u0026plusmn;\u0026thinsp;6**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e68\u0026thinsp;\u0026plusmn;\u0026thinsp;7*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCisplatin 14\u0026nbsp;mg/l, 60\u0026nbsp;min after\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e65\u0026thinsp;\u0026plusmn;\u0026thinsp;4**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72\u0026thinsp;\u0026plusmn;\u0026thinsp;5*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e69\u0026thinsp;\u0026plusmn;\u0026thinsp;4*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e104\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e151\u0026thinsp;\u0026plusmn;\u0026thinsp;7**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e57\u0026thinsp;\u0026plusmn;\u0026thinsp;7*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"7\"\u003eCisplatin was perfused for 60 minutes. Measurement of parameters of mechanical performance was carried out one minute before and 60 minutes after administration of cisplatin. Parameters were expressed as percentages of values after 60 minutes versus those at one minute before administration of cisplatin. Sham experiment was intended to show the mechanical performance of the heart in absence of drugs after 60 minutes. Eight isolated rats were used in each group.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"7\"\u003e*p\u0026thinsp;\u0026lt;\u0026thinsp;0.05; **p\u0026thinsp;\u0026lt;\u0026thinsp;0.001\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e2-Effects of rutin trihydrate (1\u0026nbsp;\u0026micro;M) on parameters of mechanical performance altered by cisplatin\u003c/p\u003e \u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e shows the effects of rutin trihydrate (1\u0026nbsp;\u0026micro;M) on alterations of the mechanical performance of isolated rat hearts induced by cisplatin (14\u0026nbsp;mg/l). Rutin trihydrate (1\u0026nbsp;\u0026micro;M) was perfused 10 minutes before administration of cisplatin. Rutin (1\u0026nbsp;\u0026micro;M) significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) reversed the reduction of left ventricular pressure induced by perfusion of hearts with 14\u0026nbsp;mg/l cisplatin for 60 minutes and attenuated the reduction in dp/dt max and dp/dt min exerted by cisplatin. There was a trend for the heart rate to increase, when hearts were perfused for 60 minutes with cisplatin (14\u0026nbsp;mg/l), but this increase did not attain statistical significance. Perfusion of hearts with rutin (1\u0026nbsp;\u0026micro;M) significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) reduced heart rate. After 60 minutes of perfusion, cisplatin (14\u0026nbsp;mg/l) significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) increased contractility index. Perfusion of hearts with rutin (1\u0026nbsp;\u0026micro;M) significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) reversed this increase in contractility index and significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) reversed the reduction in pressure- time index induced by cisplatin. When hearts were perfused for 60 minutes with cisplatin(14\u0026nbsp;mg/l), there was a tendency for the duration of diastole to decrease, but perfusion of hearts with rutin (1\u0026nbsp;\u0026micro;M) significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) increased period of diastole. There was a trend for the perfusion pressure to increase, when hearts were perfused for 60 minutes with cisplatin (14\u0026nbsp;mg/l), but this increase was statistically non-significant. Perfusion of hearts with rutin (1\u0026nbsp;\u0026micro;M) significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) reduced perfusion pressure.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eEffects of rutin trihydrate (1\u0026nbsp;\u0026micro;M) on parameters of mechanical performance altered by cisplatin (14\u0026nbsp;mg/l) in isolated hearts.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTime/parameters\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLVP %\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e+dp/dt\u003c/p\u003e \u003cp\u003e%\u003c/p\u003e\u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-dp/dt\u003c/p\u003e \u003cp\u003e%\u003c/p\u003e\u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eHR %\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eContracti lity index\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003ePressur e- time index\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eDiastolic duration\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003ePerfusion pressure\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOne min before\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUntreated 60\u0026nbsp;min after\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e94\u0026thinsp;\u0026plusmn;\u0026thinsp;9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e101\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e92\u0026thinsp;\u0026plusmn;\u0026thinsp;8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e101\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e105\u0026thinsp;\u0026plusmn;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e92\u0026thinsp;\u0026plusmn;\u0026thinsp;12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e116\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e166\u0026thinsp;\u0026plusmn;\u0026thinsp;16\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCisplatin 14\u0026nbsp;mg/l, 60\u0026nbsp;min after\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e65\u0026thinsp;\u0026plusmn;\u0026thinsp;4**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72\u0026thinsp;\u0026plusmn;\u0026thinsp;5\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e69\u0026thinsp;\u0026plusmn;\u0026thinsp;4\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e104\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e151\u0026thinsp;\u0026plusmn;\u0026thinsp;7**\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e57\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e99\u0026thinsp;\u0026plusmn;\u0026thinsp;12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e117\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCisplatin 14\u0026nbsp;mg/l\u0026thinsp;+\u0026thinsp;Rutin 1\u0026nbsp;\u0026micro;M,60\u0026nbsp;min after\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e84\u0026thinsp;\u0026plusmn;\u0026thinsp;3\u003csup\u003e##\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e85\u0026thinsp;\u0026plusmn;\u0026thinsp;6\u003csup\u003e#\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e83\u0026thinsp;\u0026plusmn;\u0026thinsp;4\u003csup\u003e#\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e86\u0026thinsp;\u0026plusmn;\u0026thinsp;6\u003csup\u003e#\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e101\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003csup\u003e##\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e82\u0026thinsp;\u0026plusmn;\u0026thinsp;5\u003csup\u003e##\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e139\u0026thinsp;\u0026plusmn;\u0026thinsp;17\u003csup\u003e#\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e84\u0026thinsp;\u0026plusmn;\u0026thinsp;2\u003csup\u003e#\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003eRutin trihydrate was administered 10 minutes before admiration of cisplatin(14\u0026nbsp;mg/l) to 8 isolated hearts. Parameters were expressed as percentages of values after 60 minutes versus those at one minute before administration of cisplatin.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003e*p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 significantly different from untreated\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003e**p\u0026thinsp;\u0026lt;\u0026thinsp;0.01 significantly different from untreated\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003e#p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 significantly different from cisplatin 14\u0026nbsp;mg/l, 60 minutes after.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003e##p\u0026thinsp;\u0026lt;\u0026thinsp;0.01 significantly different from cisplatin 14\u0026nbsp;mg/l, 60 minutes after.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e Histological Examination\u003c/p\u003e \u003cp\u003eFigure \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e: A specimen of the control group showed single, oval, and centrally located nuclei of cardiomyocytes with regularly arranged cardiac myofibers and no histopathological lesion observed in the control group. While cisplatin group showed degenerated muscle cells, necrosis of cardiac myofibers and dissolution of nuclei. The cardiac myofibres in this group were found to be in a disarrayed pattern compared to the control muscle (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). Another specimen of cisplatin specimen showed degenerated muscle cells with interstitial edema (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Addition of rutin to hearts perfused with cisplatin 14\u0026nbsp;mg/l showed a reduction in the toxic changes and the normal heart histology was significantly restored (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e Antioxidants Analysis \u003c/p\u003e \u003cp\u003ePerfusion of hearts with cisplatin 14\u0026nbsp;mg/l significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) reduced the concentration of glutathione, while perfusion of hearts with both rutin and cisplatin approximately restored the concentration of the reduced form of glutathione (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e). Whereas, perfusion of hearts with cisplatin greatly and significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) increased the concentration of malondialdehyde. Addition of Rutin to the perfusate containing cisplatin greatly reduced the tissue concentration of malondialdehyde (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e "},{"header":"Discussion","content":" \u003cp\u003eCardiac dysfunction can be demonstrated by hemodynamic changes in various parameters of cardiac function. Parameters of cardiac function assessed in this study included left ventricular pressure, heart rate, dp/dt (max), dp/dt (min), perfusion pressure, pressure-time index, contractility index and duration of diastole. Data from this study revealed that cisplatin reduced significantly left ventricular pressure, dp/dt(max), dp/dt (min) and pressure -time index in the isolated rat heart in a dose-dependent manner after perfusion for 60 minutes. In the present study, histopathological findings of heart tissues depicted that cisplatin administration induced degeneration and necrosis of cardiac muscle with the dissolution of nuclei. These observations correlate well with the alterations of hemodynamic and mechanical function induced by cisplatin. Moreover, cisplatin increased lipid peroxidation in heart tissue and reduced antioxidant activity.\u003c/p\u003e \u003cp\u003eNumerous injurious effects of cisplatin on the heart have been reported. Cisplatin has been shown to produce creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH) leakage, a progressive reduction in total carnitine and ATP and depletion of glutathione content in cardiac tissue [10]. It is also reported to produce a dose-dependent decrease in contractile force, heart rate, and coronary flow [19] and induce oxidative and nitrosative stress [10, 20]. Furthermore, it caused apoptosis [21], deterioration of diastolic cardiac function [22] oxidative stress, inflammation, and histopathological alterations [10].\u003c/p\u003e \u003cp\u003eSeveral mechanisms have been reported to explain the harmful effects of cisplatin on the myocardium. Cisplatin can generate reactive oxygen species, such as superoxide anion and hydroxyl radical [23]. These reactive oxygen species are associated with an increase in lipid peroxidation [24]. Lipid peroxidation of the cardiac membrane results in leakage of lactate dehydrogenase and creatinine kinase from cardiac myocytes [19]. Moreover, cisplatin induced a fall in plasma concentrations of various antioxidants [25]. This may lead to failure of the anti- oxidative defense mechanism against free radical-mediated organ damage. These effects are evident in the current study. Cisplatin increased lipid peroxidation, which is indicated by increased tissue concentration of malondialdehyde and reduced tissue antioxidant activity, which is indicated by reduced tissue reduced glutathione concentration. Glutathione has a direct antioxidant function by reacting with free radicals. This activity is useful in the detoxification of peroxidized lipids. Thus, it is likely that cisplatin-induced detrimental effect on the hemodynamic and mechanical function and histology of the myocardium, by increasing lipid peroxidation and reduction of glutathione tissue concentration.\u003c/p\u003e \u003cp\u003eTo overcome cisplatin-induced cardiotoxicity, numerous efforts have been made in the past [26]. In the present study, rutin trihydrate reversed the harmful effects of cisplatin on left ventricular pressure, dp/dt(max), dp/dt(min), contractility index, pressure- time index, heart rate, duration of diastole and perfusion pressure. Moreover, cisplatin restored the normal histology of the myocardium, inhibited lipid peroxidation, and increased reduced glutathione concentration. Coronary blood flow is impeded during systole, the duration of diastole is an important determinant of coronary blood flow and subendocardial perfusion. Rutin trihydrate by prolonging the duration of diastole and reducing perfusion pressure could greatly improve coronary blood flow and subendocardial perfusion.\u003c/p\u003e \u003cp\u003eCisplatin causes cardio-toxic effects by oxidative stress and decrease in antioxidant enzymes [11]. Rutin has been previously reported for beneficial protective effects against variety of drug induced toxicities including doxorubicin and cisplatin induced cardiac toxicity [12\u0026ndash;14]. The protective effects of rutin trihydrate observed in our current study mostly likely occurred due to its profound anti-oxidant properties. This protective effect of rutin trihydrate could be attributed to its antioxidant property. Rutin trihydrate has been shown to enhance superoxide dismutase (SOD) and 1,1-diphenyl-2-picrylhydrazyl (DPPH) activity [27] and reduced lipid peroxide content increased by cisplatin in kidneys of rats [28\u0026ndash;29]. Moreover, rutin is reported to have anti-inflammatory and anti-apoptotic effects. It inhibited NFκB and TNF-α pathway mediated inflammation and caspase-3 cell apoptosis [30].\u003c/p\u003e \u003c/p\u003e "},{"header":"Conclusion","content":" \u003cp\u003eCisplatin-induced dose-dependent impairment of several parameters of cardiac function, induced histopathological alterations, and reduced antioxidant activity. These harmful effects of cisplatin were ameliorated by rutin trihydrate. Cisplatin the ability of rutin to ameliorate cisplatin-induced cardiotoxicity could be attributed to its antioxidant effects.\u003c/p\u003e \u003cp\u003eThe attenuation of the detrimental effects of cisplatin by rutin trihydrate could have eventual clinical implications in terms of more rational usage of this agent. Rutin trihydrate appears to be a potential candidate to ameliorate cardiotoxicity associated with cisplatin in rats. Hence, it would be worthwhile studying the effects of rutin trihydrate supplementation in cisplatin-treated cancer patients, in the hope of reducing cisplatin-induced cardiotoxicity.\u003c/p\u003e "},{"header":"Abbreviations","content":"\u003cp\u003e CK-MB: creatine kinase-MB; DTNB: 5.5-dithiobis-(2 nitrobenzoic acid; +dp/dt(max):Rate of maximum change of left ventricular contraction; -dp/dt(min): rate of minimum change of left ventricular relaxation; GSH: Reduced glutathione; LDH: lactate dehydrogenase; LVP: left ventricular pressure; MDA: Malondialdehyde; TNF-α: Tumor necrosis factor alpha; TBA: thiobarbituric acid\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors extend their appreciation to the Deanship of Scientific Research at King Saud University, Riyadh for funding this work through research group (RG\u0026ndash;1439\u0026ndash;002).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;IAB is the main author, contributed in funding, methodology, analyzed the data, wrote and revised the manuscript. OY contributed in the methodology and helped and data analysis and revising the manuscript. RL contributed in the experimental work and data compilation and manuscript writing. SF contributed in the experimental work and data compilation. FV contributed in the literature review and data anlysis. SA contribute in data compilation, analysis and literature review and data.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;There is no funding to declare.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;The authors confirm that the data supporting the findings of this study are available within the article.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe experiments were conducted following the ethical guidelines for investigation in laboratory animals, and the College of Medicine, King Saud University Riyadh.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;Not applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eSleijfer DTh, Meijer S,Mulder NH. Cisplatin: a review of clinical applications and renal \u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026nbsp; Pharm Weekbl [Sci]. 1985;7: 237-44.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Tsang%20RY%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19916578\"\u003eTsang RY\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Al-Fayea%20T%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19916578\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Al-Fayea%20T%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19916578\"\u003eAl\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Al-Fayea%20T%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19916578\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Al-Fayea%20T%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19916578\"\u003eFayea T\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Al-Fayea%20T%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19916578\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Au%20HJ%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19916578\"\u003eAu HJ.\u003c/a\u003e Cisplatin overdose: toxicities and management. \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/19916578\"\u003eDrug \u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/19916578\"\u003eSaf\u003c/a\u003e. 2009; 32:1109-22.\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eKhan S, Chen CL, Brady MS, \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Parameswaran%20R%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22585705\"\u003eParameswaran R\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Parameswaran%20R%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22585705\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Moore%20R%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22585705\"\u003eMoore R\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Moore%20R%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22585705\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Hassoun%20H%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22585705\"\u003eHassoun H\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Hassoun%20H%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22585705\"\u003e,\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Carvajal%20RD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22585705\"\u003eCarvajal RD\u003c/a\u003e\u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Carvajal%20RD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22585705\"\u003e.\u003c/a\u003e Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma. J Clin Oncol. 2012; 30: e163\u0026ndash;4.\u003c/li\u003e\n\u003cli\u003eTassinari D, Sartori S, Drudi G, Panzini I, Gianni L, Pasquini E, \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Abbasciano%20V%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9496393\"\u003eAbbasciano V\u003c/a\u003e\u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Abbasciano%20V%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9496393\"\u003e,\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Ravaioli%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9496393\"\u003eRavaioli A\u003c/a\u003e\u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Ravaioli%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9496393\"\u003e,\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Iorio%20D%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9496393\"\u003eIorio D.\u003c/a\u003e Clinical case; Cardiac arrhythmias after cisplatin infusion: Three case reports and a review of the literature. Ann of Oncol. 1997; 8:1263-1267.\u003c/li\u003e\n\u003cli\u003eKucharz J, Michalowska-Kaczmarczyk A, Zygulska AL, Wojtak J, Pawlik W,Herman RM, Krzemieniecki K. Bradycardia as a rare symptom of cisplatin cardiotoxicity.\u0026nbsp; Oncol Lett. 2016;11:2297-2299.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://psjd.icm.edu.pl/psjd/contributor/a163659047659f700f0b18f407f3efa1\"\u003eSawant\u003c/a\u003e SP, \u003ca href=\"http://psjd.icm.edu.pl/psjd/contributor/d93bf4408ccd8d2edc24026b842692c4\"\u003ePrakruthi\u003c/a\u003e J, \u003ca href=\"http://psjd.icm.edu.pl/psjd/contributor/9ae39ae4cfbea2ceb18e899fb981eede\"\u003eDaddi\u003c/a\u003e AD,\u003ca href=\"http://psjd.icm.edu.pl/psjd/contributor/e38147bf41a99e640f01eb1ee5525ae3\"\u003e\u0026nbsp; \u003c/a\u003e\u003ca href=\"http://psjd.icm.edu.pl/psjd/contributor/e38147bf41a99e640f01eb1ee5525ae3\"\u003eGhosh\u003c/a\u003e J , \u003ca href=\"http://psjd.icm.edu.pl/psjd/contributor/9285fb2a58518bbac2acdef7a71656b2\"\u003eJoshi\u003c/a\u003e A , \u003ca href=\"http://psjd.icm.edu.pl/psjd/contributor/d23dde52e793cc4f0ca65e899c43c026\"\u003e\u0026nbsp;\u003c/a\u003e\u003ca href=\"http://psjd.icm.edu.pl/psjd/contributor/d23dde52e793cc4f0ca65e899c43c026\"\u003eDhir\u003c/a\u003e Cisplatin-induced cardiotoxicity \u0026ndash; two case reports. \u003ca href=\"http://psjd.icm.edu.pl/psjd/element/bwmeta1.element.psjd-c1ff8691-57a0-495a-b711-50874b23c49e\"\u003eOnco Rev\u003c/a\u003e. 2015\u003ca href=\"http://psjd.icm.edu.pl/psjd/element/bwmeta1.element.psjd-dc8a774a-139e-4b60-8685-31622aaf650c\"\u003e;\u003c/a\u003e \u003ca href=\"http://psjd.icm.edu.pl/psjd/element/bwmeta1.element.psjd-dc8a774a-139e-4b60-8685-31622aaf650c\"\u003e5\u003c/a\u003e : A145-150.\u003c/li\u003e\n\u003cli\u003eJakubowski AA, Kemeny N. Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. Cancer 1988\u003ca href=\"http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19880715)62:2%3C%3E1.0.CO;2-C/issuetoc\"\u003e; \u003c/a\u003e\u003ca href=\"http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19880715)62:2%3C%3E1.0.CO;2-C/issuetoc\"\u003e62:\u003c/a\u003e 266\u0026ndash;269.\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eOzcan\u003ca href=\"http://www.omicsonline.org/recurrent-complete-atrioventricular-block-during-cisplatin-infusion-a-case-report-2155-9880.1000151.php?aid=1870#A1\"\u003eT\u003c/a\u003e\u003ca href=\"http://www.omicsonline.org/recurrent-complete-atrioventricular-block-during-cisplatin-infusion-a-case-report-2155-9880.1000151.php?aid=1870#A1\"\u003e,\u003c/a\u003e Cirit A, Kiykim A. Recurrent Complete atrioventricular block during cisplatin infusion.A case report. J Clinic Experiment Cardiol. 2011; 2:151.\u003c/li\u003e\n\u003cli\u003eBrillet G, Deray G, Baumelou A, Jacobs C. Acute cardiac and renal failure after 5FU and cisplatin treatment. Nephron 1991; 59:667-668.\u003c/li\u003e\n\u003cli\u003eAl-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa MA, Al-Rejaie SS, AlShabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin- induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006; 53: 278\u0026ndash; 286.\u003c/li\u003e\n\u003cli\u003eDemir F, Narin F, Akg\u0026uuml;n H, \u0026Uuml;z\u0026uuml;m K, Saraymen R, Baykan A, et al. Effects of melatonin on experimental cardiotoxicity induced by doxorubicin. \u0026Ccedil;ocuk Sağ Hast Derg. 2004; 47: 260-8.\u003c/li\u003e\n\u003cli\u003eFei J, Sun Y, Duan Y, Xia J, Yu S, Ouyang P, Wang T, Zhang G. Low concentration of rutin treatment might alleviate the cardiotoxicity effect of pirarubicin on cardiomyocytes via activation of PI3K/AKT/mTOR signaling pathway. Biosci Rep. 2019; 39(6).\u003c/li\u003e\n\u003cli\u003eTopal İ, \u0026Ouml;zbek Bilgin A, Keskin \u0026Ccedil;imen F, Kurt N, S\u0026uuml;leyman Z, Bilgin Y, \u0026Ouml;z\u0026ccedil;i\u0026ccedil;ek A, Altuner D. The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol J Cardiol. 2018;136-142.\u003c/li\u003e\n\u003cli\u003eRamalingayya GV, Cheruku SP, Nayak PG, Kishore A, Shenoy R, Rao CM, Krishnadas N. Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats. Drug Des Devel Ther. 2017;10: 11-1026.\u003c/li\u003e\n\u003cli\u003eSabuncuoğlu S, \u0026Ouml;zg\u0026uuml;neş H. Cisplatin toxicity: Importance of oxidative stress and effect of antioxidants. J Ist Faculty Med. 2011; 74: 18-25.\u003c/li\u003e\n\u003cli\u003eSakamoto M, Kaga K, Kamio T. Extended high-frequency ototoxicity induced by the first administration of cisplatin. Otolaryngol Head Neck Surg. 2000; 122: 828-33.\u003c/li\u003e\n\u003cli\u003eOwens CW, Belcher RV. A colorimetric micro-method for the determination of glutathione biochem j. 1965; 94:705-11.\u003c/li\u003e\n\u003cli\u003eBuege JA, Aust SD. Microsomal lipid peroxidation. Method Enzymol. 1978; 52:302-10.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Misic%20MM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003eMisic MM\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Misic%20MM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Jakovljevic%20VL%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003eJakovljevic VL\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Jakovljevic%20VL%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Bugarcic%20ZD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003eBugarcic ZD\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Bugarcic%20ZD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Zivkovic%20VI%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003eZivkovic VI\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Zivkovic%20VI%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Srejovic%20IM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003eSrejovic IM\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Srejovic%20IM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Barudzic%20NS%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003eBarudzic NS\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Barudzic%20NS%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003e,\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Djuric%20DM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003eDjuric DM\u003c/a\u003e\u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Djuric%20DM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003e,\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Novokmet%20SS%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003eNovokmet SS\u003c/a\u003e\u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Novokmet%20SS%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=25404470\"\u003e.\u003c/a\u003e Platinum Complexes-Induced cardiotoxicity of isolated perfused rat heart: Comparison of Pt (II) and Pt (IV) Analogues Versus Cisplatin. Cardiovasc. Toxicol. 2015;15: 261-8.\u003c/li\u003e\n\u003cli\u003eDemkow U, Białas-Chromiec B, Stelmaszczyk-Emmel A, Radzikowska E, Wiatr, E, Radwan-Rohrenschef P, Szturmowicz M. The cardiac markers and oxidative stress parameters in advanced non-small cell lung cancer patients receiving cisplatin-based chemotherapy. eJIFCC. 2011; 14:6-15.\u003c/li\u003e\n\u003cli\u003eEl-Sawalhi MM, Ahmed LA. Exploring the protective role of apocynin, a specific NADPH oxidase inhibitor in cisplatin-induced cardiotoxicity in rats. \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/24291008\"\u003eChem Biol\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/24291008\"\u003eInteract\u003c/a\u003e. 2014; 207:58-66.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Altena%20R%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003eAltena R\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Altena%20R%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Haas%20EC%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003ede Haas EC\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Haas%20EC%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Nuver%20J%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003eNuver J\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Nuver%20J%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Brouwer%20CA%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003eBrouwer CA\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20den%20Berg%20MP%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003e,\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20den%20Berg%20MP%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003evan den Berg MP\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20den%20Berg%20MP%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Smit%20AJ%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003eSmit AJ\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Smit%20AJ%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003e,\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Postma%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003ePostma A\u003c/a\u003e\u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Postma%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003e,\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Sleijfer%20DT%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003eSleijfer DT\u003c/a\u003e\u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Sleijfer%20DT%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003e,\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Gietema%20JA%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=19455138\"\u003eGietema JA.\u003c/a\u003e Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br. J. Can. 2014; 100:1861-1866.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Wozniak%20K%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=15135086\"\u003eWozniak K\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Wozniak%20K%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=15135086\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Czechowska%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=15135086\"\u003eCzechowska A\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Czechowska%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=15135086\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Blasiak%20J%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=15135086\"\u003eBlasiak J\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Blasiak%20J%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=15135086\"\u003e.\u003c/a\u003e Cisplatin- evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Chemo Biol Inter. 2004; 147:309-318.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Antunes%20LM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=10704263\"\u003eAntunes LM\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Antunes%20LM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=10704263\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Darin%20JD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=10704263\"\u003eDarin JD\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Darin%20JD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=10704263\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Bianchi%20MD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=10704263\"\u003eBianchi MD\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Bianchi%20MD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=10704263\"\u003e.\u003c/a\u003e Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res. 2011; 41:405-411.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Weijl%20NI%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003eWeijl NI\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Weijl%20NI%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Hopman%20GD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003eHopman GD\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Hopman%20GD%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Wipkink-Bakker%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003eWipkink\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Wipkink-Bakker%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Wipkink-Bakker%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003eBakker A\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Wipkink-Bakker%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003e.\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Lentjes%20EG%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003eLentjes EG\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Lentjes%20EG%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Berger%20HM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003eBerger HM\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Berger%20HM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Cleton%20FJ%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003eCleton FJ\u003c/a\u003e \u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Osanto%20S%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003eOsanto S\u003c/a\u003e\u003ca href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Osanto%20S%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=9932164\"\u003e.\u003c/a\u003e Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/9932164\"\u003eAnn Oncol\u003c/a\u003e.1998; 2000: 1331-7.\u003c/li\u003e\n\u003cli\u003e20\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-Awady%20el-SE%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-Awady%20el-SE%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003eEl\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-Awady%20el-SE%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-Awady%20el-SE%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003eAwady SE\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-Awady%20el-SE%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Moustafa%20YM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003eMoustafa YM\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Moustafa%20YM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abo-Elmatty%20DM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003eAbo\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abo-Elmatty%20DM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abo-Elmatty%20DM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003eElmatty DM\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abo-Elmatty%20DM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Radwan%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003eRadwan A\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Radwan%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21034734\"\u003e.\u003c/a\u003e Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/21034734\"\u003eEur J Pharmacol\u003c/a\u003e. 2011; 650: 335-41.\u003c/li\u003e\n\u003cli\u003e21\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Bhandary%20B%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Bhandary%20B%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003eBhandary B\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Bhandary%20B%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Piao%20CS%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003ePiao CS\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Piao%20CS%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20DS%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003eKim DS\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20DS%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20GH%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003eLee GH\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20GH%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Chae%20SW%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003eChae SW\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Chae%20SW%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20HR%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003eKim HR\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20HR%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=22870819\"\u003e,\u003c/a\u003eChae HJ. The Protective Effect of Rutin against ischemia/reperfusion-associated hemodynamic alteration through antioxidant activity. Arch Pharm Res. 2012; 35: 1091-1097.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Kamel%20KM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003eKamel KM\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Kamel%20KM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abd%20El-Raouf%20OM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003eAbd El\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abd%20El-Raouf%20OM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abd%20El-Raouf%20OM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003eRaouf OM\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abd%20El-Raouf%20OM%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Metwally%20SA%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003eMetwally SA\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Metwally%20SA%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abd%20El-Latif%20HA%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003eAbd El\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abd%20El-Latif%20HA%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abd%20El-Latif%20HA%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003eLatif HA\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Abd%20El-Latif%20HA%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-sayed%20ME%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003eEl\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-sayed%20ME%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-sayed%20ME%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003esayed ME\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=El-sayed%20ME%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=24819883\"\u003e.\u003c/a\u003e Hesperidin and rutin, antioxidant citrus flavonoids, attenuate cisplatin-induced nephrotoxicity in rats. \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/24819883\"\u003eJ Biochem Mol Toxicol\u003c/a\u003e. 2014; 28: 312-9.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.informaticsjournals.com/index.php/jnr/search/authors/view?firstName=A.\u0026amp;middleName=\u0026amp;lastName=Sreedevi\u0026amp;affiliation=\u0026amp;country=IN\"\u003eSreedevi \u003c/a\u003eA, \u003ca href=\"http://www.informaticsjournals.com/index.php/jnr/search/authors/view?firstName=K.\u0026amp;middleName=\u0026amp;lastName=Bharathi\u0026amp;affiliation=\u0026amp;country=IN\"\u003e\u0026nbsp;\u003c/a\u003e\u003ca href=\"http://www.informaticsjournals.com/index.php/jnr/search/authors/view?firstName=K.\u0026amp;middleName=\u0026amp;lastName=Bharathi\u0026amp;affiliation=\u0026amp;country=IN\"\u003eBharathi \u003c/a\u003e\u003ca href=\"http://www.informaticsjournals.com/index.php/jnr/search/authors/view?firstName=K.\u0026amp;middleName=\u0026amp;lastName=Bharathi\u0026amp;affiliation=\u0026amp;country=IN\"\u003e\u0026nbsp;\u003c/a\u003eK\u003ca href=\"http://www.informaticsjournals.com/index.php/jnr/search/authors/view?firstName=K.%20V.%20S.%20R.%20G.\u0026amp;middleName=\u0026amp;lastName=Prasad\u0026amp;affiliation=\u0026amp;country=IN\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.informaticsjournals.com/index.php/jnr/search/authors/view?firstName=K.%20V.%20S.%20R.%20G.\u0026amp;middleName=\u0026amp;lastName=Prasad\u0026amp;affiliation=\u0026amp;country=IN\"\u003ePrasad \u003c/a\u003e\u003ca href=\"http://www.informaticsjournals.com/index.php/jnr/search/authors/view?firstName=K.%20V.%20S.%20R.%20G.\u0026amp;middleName=\u0026amp;lastName=Prasad\u0026amp;affiliation=\u0026amp;country=IN\"\u003e\u0026nbsp;\u003c/a\u003e Protective Effect of Rutin against cisplatin-induced nephrotoxicity in rats. J Nat Rem. \u003ca href=\"http://www.informaticsjournals.org/index.php/jnr/issue/view/18\"\u003e2010\u003c/a\u003e\u003ca href=\"http://www.informaticsjournals.org/index.php/jnr/issue/view/18\"\u003e; \u003c/a\u003e\u003ca href=\"http://www.informaticsjournals.org/index.php/jnr/issue/view/18\"\u003e10:\u003c/a\u003e \u003ca href=\"http://www.informaticsjournals.org/index.php/jnr/issue/view/18\"\u003e144\u003c/a\u003e\u003ca href=\"http://www.informaticsjournals.org/index.php/jnr/issue/view/18\"\u003e-\u003c/a\u003e\u003ca href=\"http://www.informaticsjournals.org/index.php/jnr/issue/view/18\"\u003e151\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Arjumand%20W%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21605616\"\u003eArjumand W\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Arjumand%20W%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21605616\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Seth%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21605616\"\u003eSeth A\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Seth%20A%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21605616\"\u003e,\u003c/a\u003e \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Sultana%20S%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21605616\"\u003eSultana S\u003c/a\u003e\u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=Sultana%20S%5BAuthor%5D\u0026amp;cauthor=true\u0026amp;cauthor_uid=21605616\"\u003e.\u003c/a\u003e Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NF\u0026kappa;B, TNF-\u0026alpha; and caspase-3 expression in wistar rats. \u003ca href=\"http://www.ncbi.nlm.nih.gov/pubmed/21605616\"\u003eFood Chem Toxicol\u003c/a\u003e. 2011; 49: 2013-21.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"cisplatin, rutin trihydrate, cardiac function, histology, oxidative stress","lastPublishedDoi":"10.21203/rs.3.rs-26078/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-26078/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eThe present study aims to investigate the protective effect of rutin against cisplatin induced toxic effects on the mechanical performance of the myocardium, histopathology, and oxidative stress in isolated perfused rat hearts.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eCardiotoxicity of cisplatin was assessed at three dosage levels (1, 7, and 14\u0026nbsp;mg/l) in the isolated perfused rat hearts. The toxic effect of cisplarin was assessed on left ventricular pressure (LVP), heart rate (HR), dp/dt(max), dp/dt (min), perfusion pressure, pressure-time index, contractility index and duration of diastole. Measurements were carried out one minute before perfusion of cisplatin and 60 minutes after perfusion.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eCisplatin reduced significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) in a dose-dependent manner LVP, dp/dt(max), dp/dt(min) and pressure- time index. Perfusion of rutin trihydrate (1\u0026nbsp;\u0026micro;M/l), 10 minutes before administration of cisplatin and throughout the experiment significantly (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) attenuated the detrimental effects of cisplatin on cardiac parameters. Cisplatin caused degeneration and necrosis of cardiac muscle cells, while rutin reduced these changes and restored normal heart histology. Moreover, cisplatin reduced the myocardium concentration of reduced glutathione and increased the level of malondialdehyde, whereas rutin almost reversed these changes.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eCisplatin-induced dose-dependent impairment of several parameters of cardiac function and produced histopathological alterations in isolated rat hearts. These harmful effects of cisplatin were ameliorated by rutin trihydrate. These findings suggest the potential protective effects of rutin trihydrate against cisplatin-induced cardiotoxicity.\u003c/p\u003e","manuscriptTitle":"Rutin trihydrate attenuated cisplatin- induced cardiac toxicity in isolated perfused rat’s hearts","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2020-05-11 19:11:54","doi":"10.21203/rs.3.rs-26078/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d2911153-7969-4550-84ea-d3f9d69b1503","owner":[],"postedDate":"May 11th, 2020","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":97820,"name":"General Practice"}],"tags":[],"updatedAt":"2020-05-29T02:59:46+00:00","versionOfRecord":[],"versionCreatedAt":"2020-05-11 19:11:54","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-26078","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-26078","identity":"rs-26078","version":["v1"]},"buildId":"_2-kVJe1T_tPrBINL-cwx","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}